Introduction
Sarcoidosis is a multi-systemic disorder of unknown cause which is characterized by the presence of non-caseating granulomas in target organs. Ninety percent of sarcoidosis cases have thoracic involvement.
1,2 The highest annual incidence of sarcoidosis has been observed in northern European countries (5-40 cases per 100 000 people). 3 Phenotypically, sarcoidosis follows either an acute or chronic course. Up to 70% of patients present with acute sarcoidosis and experience self-limiting disease which will resolve within 1-2 years. 4 In contrast, 30-50% of patients will develop persistent pulmonary sarcoidosis for which no approved treatments are currently available and corticosteroid use is the standard, non-specific treatment method. 4 Although mechanisms underlying the development of sarcoidosis are currently unknown, it hypothesized to be caused by an aberrant host immune response to unknown environmental antigens in genetically pre-disposed individuals. A number of alterations in sarcoidosis patients' immune responses have been reported including, an exaggerated Th1 response, increased Th17 activity, attenuated regulatory T cell responses and oligoclonal expansion of CD4þ T cell responses, which is consistent with chronic antigenic stimulation. [5] [6] [7] [8] [9] To date, no specific pathogen has been identified as a causative factor in sarcoidosis. Several studies have a role for mycobacterial or propionibacterial organisms in the pathogenesis of sarcoidosis. Specifically, a meta-analysis of studies carried out between 1980 and 2006 demonstrated that 26% of all sarcoidosis tissues had evidence of mycobacterial nucleic acids. 10 In the context of viral infection, seroepidemiological studies have demonstrated significant levels of antibodies to Epstein-Barr virus (EBV), rubella and parainfluenza 3 in sarcoidosis. 11 However, no correlation could be made between viral antibody titre and stage of disease or activity.
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In this study, we investigated the role of defective TLR3 in the development of persistent clinical disease in pulmonary sarcoidosis. TLR3 has previously been shown to bind dsRNA from viruses, bacteria and helminths, respectively, in addition to mRNA released from necrotic cells. 2, [12] [13] [14] [15] Specifically, here we investigated the role of the TLR3 polymorphism, Leu412Phe (TLR3 Leu412Phe, L412F; rs3775291) as a causative factor in the development of and in disease persistence in pulmonary sarcoidosis, respectively. Previously, we identified a role for TLR3 L412F in accelerated disease progression and increased risk of mortality in idiopathic pulmonary fibrosis (IPF). 16 TLR3 L412F has also been implicated as a causative factor in a number of autoimmune and inflammatory diseases such as diabetes, systemic lupus erythematosus and rheumatoid arthritis, [17] [18] [19] as well as a variety of cancers. [20] [21] [22] [23] [24] TLR3 L412F has also been demonstrated to have either a protective or pathogenic effect in viral infection. 25, 26 In this study, we report a significant association between development of a persistent clinical phenotype in pulmonary sarcoidosis and the TLR3 L412F variant in cohorts of Irish and American Caucasians, respectively. Furthermore, activation of TLR3 in vitro in primary human lung fibroblasts from 412 F-homozygous patients resulted in decreased TLR3 and IFN-b expression, reduced apoptosis and dysregulated proliferation, respectively, compared with fibroblasts from TLR3 wild-type patients. Our findings imply that defective TLR3 promotes a persistent disease phenotype in sarcoidosis and reveals TLR3 L412F as a candidate prognostic biomarker in this interstitial lung disease.
Materials and methods

Study subjects
A cohort of Irish Caucasian pulmonary sarcoidosis patients (n ¼ 228; Table 1 ) was recruited from St Vincent's University Hospital, Elm Park, Dublin 4 (SVUH). A cohort of Irish Caucasian healthy volunteers (n ¼ 263) was additionally recruited as a control group. Genomic DNA was obtained from the American cohort of sarcoidosis patients attending the specialized Sarcoidosis Clinic at Johns Hopkins University School, Baltimore, MA, USA (n ¼ 123; Table 1 ).
Diagnosis of pulmonary sarcoidosis and classification of persistent disease
Irish and American pulmonary sarcoidosis patients were diagnosed at initial hospital presentation by the same physician (S.C.D. and D.R.M), respectively, and followed-up for at least TLR3 L412F genotyping TLR3 L412F genotyping was carried out as described by us previously in a parallel study investigating the role of the TLR3 L412F in IPF 16 (Supplementary Methods).
Analysis of TLR3 L412F functionality in primary human lung fibroblasts from pulmonary sarcoidosis patients
Primary fibroblast cell lines were isolated from lung biopsies of sarcoidosis patients (supplied by SVUH) and cultured as described previously 27 (Supplementary Methods). Methodology pertaining to the analysis of the effects of TLR3 L412F on fibroblast-apoptosis, -proliferation and -cytokine/interferon production, respectively, is detailed in the Supplementary Methods Section.
Statistical analysis
All statistical analyses were carried out using GraphPad Instat Software (GraphPad Software Inc. CA, USA). variance was used to test for statistical significance (two-tailed analysis) between experimental groups of three. Multiple comparisons between groups were then assessed using the Tukey-Kramer post-hoc test (for parametric analysis) or Dunn's post-hoc test (for non-parametric analysis). Statistical significance was recorded at P < 0.05.
Results
TLR3 L412F (rs3775291) is not associated with development of pulmonary sarcoidosis in Irish patients
In this study, we tested for an association between TLR3 L412F and development of pulmonary sarcoidosis in an Irish casecontrol study of 263 control subjects and 228 sarcoidosis cases ( 
Primary lung fibroblasts from TLR3 L412F homozygote sarcoidosis patients produce reduced IL-8 and IFN-b, and have reduced TLR3 expression
In order to elucidate the mechanisms underlying the association between development of persistent disease and TLR3 412 F, we investigated TLR3 function in primary human fibroblasts *P < 0.05, **P < 0.01, ***P < 0.001: Poly(I:C) 100 lg/ml compared with Medium-only at 24 h post-treatment. þþP < 0.01: Poly(I:C) 100 lg/ml in fibroblasts from Phe/ Phe (n ¼ 3) compared with Leu/Leu patients (n ¼ 3). Results shown are the mean 6 SEM of (B, C) three or (A) six replicates from a representative of (B) two or (A, C) three separate experiments.
from TLR3 412 F wild-type (Leu/Leu) vs. homozygous (Phe/Phe) sarcoidosis patients with a persistent disease phenotype. Following TLR3 activation by Poly(I:C) treatment, variant Phe/ Phe fibroblasts had significantly reduced IL-8 production ( Figure 1A ; NF-jB-readout) and IFN-b expression ( Figure 1B ; IRF3-readout), respectively. These findings conferred with the authors who first described the polymorphism and who reported that it resulted in defective TLR3 function via reduced NF-jB and IRF3 signalling. 28 In addition, following TLR3 activation by Poly(I:C) treatment, variant Phe/Phe fibroblasts also had blunted TLR3 mRNA expression compared with wild-type fibroblasts ( Figure 1C) . We have also shown additionally using FACS that the upregulation of extracellular TLR3 following Poly(I:C) treatment on Phe/Phe primary lung fibroblasts was blunted compared with wild-type cells (Supplementary Figure S1A) . In contrast, levels of intracellular TLR3 expression on wild-type and Phe/Phe fibroblasts were comparable following Poly(I:C) treatment (Supplementary Figure S1B) .
TLR3 L412F inhibits apoptosis and dysregulates proliferation in primary lung fibroblasts from homozygote sarcoidosis patients
Here, we assessed the induction of TLR3-induced apoptosis in Leu/Leu and Phe/Phe fibroblasts and found a significantly reduced ability of Phe/Phe fibroblasts to undergo late-phase apoptosis compared with wild-type cells (Figure 2A and B) . Furthermore, we also observed a decreased ability of Phe/Phe cells to reduce their proliferation in response to Poly(I:C) compared with Leu/Leu cells ( Figure 3A ). Interestingly, a comparable level of reduction in fibroproliferation was observed following treatment of primary human lung fibroblasts for 24 h with 1000 IU/ml IFN-b in cells from Leu/Leu and Phe/Phe patients ( Figure 3B ). This result suggests that the dysregulated fibroproliferation seen in TLR3 defective, Phe/Phe fibroblasts may be due to their reduced ability to produce IFN-b.
Discussion
In this study, we investigated the role of defective TLR3 in the pathogenesis of pulmonary sarcoidosis. Specifically, we investigated the role of the TLR3 polymorphism, TLR3 L412F (rs3775291), as a causative factor in the development of, and in disease persistence in pulmonary sarcoidosis, respectively. Previously, we identified a role for TLR3 L412F in accelerated disease progression and increased risk of mortality in IPF. 16 In this study, we established that TLR3 L412F was not associated with development of pulmonary sarcoidosis but was significantly associated with disease persistence. Irish patients who presented with sarcoidosis, and who were TLR3 412 F-homozygous, were significantly more likely to develop persistent disease. Therefore, these findings suggest that TLR3 L412F plays a broader role in interstitial lung disease and that its pathogenic effects are not limited to IPF. In this study, the association between TLR3 L412F and disease persistence in Irish pulmonary sarcoidosis patients was validated in a modest-sized American cohort of patients, attending a tertiary referral centre. American pulmonary sarcoidosis patients who had one copy of the variant allele were almost five times more likely to develop persistent disease. Interestingly, there was also a significant association between disease persistence and race. When Caucasian American and African American populations were analysed individually, a significant association was found between the 412 F allele and disease persistence in Caucasian Americans but not in African Americans. This may reflect specific genetic backgrounds in Caucasian Americans compared to African Americans which results in different spectrums of disease presentations in both populations. These novel results merit further investigation using larger cohort-size.
Here, we also report that primary lung fibroblasts from TLR3 412 F-homozygous pulmonary sarcoidosis patients had reduced IL-8, IFN-b and TLR3 production or expression, reduced fibroblast apoptosis and dysregulated fibroproliferative responses compared with cells from wild-type patients, following TLR3-activation. Our findings imply that defective TLR3 promotes a persistent disease phenotype in sarcoidosis by dysregulating apoptotic and fibroproliferative processes via an IFN-b-dependent process. Thus, this study identifies defective TLR3 function as a previously undescribed factor in the development of persistent clinical disease in pulmonary sarcoidosis and reveals the TLR3 signalling pathway as a novel therapeutic target in its treatment (see Supplementary Figure S2 for schematic of proposed mechanism). The strength of this study lies in its exploration of the role of the change in primary lung fibroblast function in disease persistence in pulmonary sarcoidosis patients, in the context of the TLR3 L412F polymorphism. In this study, primary lung fibroblasts from three patients from each respective genotype were utilized (i.e. TLR3 Leu/Leu wild-type and TLR3 Phe/ Phe homozygote patients). In future studies to investigate the role of TLR3 L412F further in the pathogenesis of persistent pulmonary sarcoidosis, and as a candidate prognostic marker, additional lung fibroblasts from wild-type and homozygote patients will be recruited.To date, no specific pathogen has been identified as a causative factor in sarcoidosis. Several studies have a role for mycobacterial or propionibacterial organisms in the pathogenesis of sarcoidosis. Previously, a human herpes 8 open reading frame DNA was detected in a significantly higher proportion of sarcoid-compared with non-sarcoid lung tissue. 29 However, the role of these viruses, and of EBV particularly, in the etiology of sarcoidosis remains speculative.
11,29 TLR3 was originally identified as an anti-viral receptor and was shown to bind viral dsRNA. 12 More recently, the role for TLR3 in microbial infection has been expanded. TLR3 is now known to additionally bind dsRNA from bacteria and helminths. 13, 14 It has also been shown to bind mRNA which has been released from necrotic cells during infection and inflammation. 15 In this study, the defective function associated with the effects of TLR3 L412F in cells from 412 F-homozygous patients would provide a mechanism by which bacterial or viral infection could promote a persistent clinical phenotype in sarcoidosis.
In this study, we also observed that reduced IFN-b expression or production is one of the mechanisms by which TLR3 L412F mediates its effects. In the context of IFN-b, this has been shown to directly induce apoptosis in cells following TLR3 activation in an autocrine manner. 30 Interestingly, the addition of this makes their use possible if indicated. However, their effect in persistent forms of the disease needs further evaluation. 35 Sarcoidosis can follow a variable clinical course. Historically, it is well recognized that presentation with erythema nodosum and bilateral hilar adenopathy on chest radiograph has a better prognosis (15% risk of chronicity and progression) compared to presentation with bilateral chest radiograph infiltrates (40% chance of progression). However, we are unable to stratify, with a high degree of accuracy, the prognosis of individual patients at presentation. This is a significant clinical unmet need in clinical practice and in clinical trials design. It would be of significant advantage in clinical trials if we could enrich patient recruitment favoring a more aggressive clinical phenotype. This would offer the best opportunity of assessing whether specific, proposed therapies are clinically efficacious or not. This study reveals TLR3 L412F as a candidate prognostic biomarker in pulmonary sarcoidosis.
Conclusion
In conclusion, this study reveals for the first time that defective TLR3 function, and specifically TLR3 L412F-homozygosity, are important factors in driving a persistent clinical phenotype in pulmonary sarcoidosis patients. This study also suggests that restoration of TLR3-function may provide a novel therapeutic strategy in the treatment of sarcoidosis. 
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